Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5612999 | 0.92 | BRAF (0.47) | BRD4L3MBTL1METAP2BRAFMAPT | |
| SCHEMBL5612905 | 0.86 | METAP2 (0.61) | METAP2BRAFMAPTF2KDM4E | |
| SCHEMBL5612752 | 0.76 | METAP2 (0.46) | METAP2KDM4E | |
| SCHEMBL5020113 | 0.74 | BRD4 (0.56) | BRD4L3MBTL1METAP2BRAFMAPT | |
| SCHEMBL5612898 | 0.73 | HPGD (0.53) | METAP2BRAFMAPTMEN1KMT2A | |
| SCHEMBL5613146 | 0.73 | PIK3CA (0.45) | METAP2MAPTMEN1KMT2A | |
| SCHEMBL1646236 | 0.73 | GP6 (0.37) | METAP2MEN1KMT2A | |
| SCHEMBL6170747 | 0.73 | CYP1A2 (0.52) | MAPTMEN1KMT2AKDM4EHIF1A | |
| SCHEMBL5613128 | 0.72 | KDM4E (0.46) | METAP2MAPTMEN1KMT2AKDM4E | |
| SCHEMBL5613044 | 0.71 | KMT2A (0.57) | MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | claimed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | claimed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | claimed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-20070077641-A1 | Methionine aminopeptidase and methods of use | PALMER LESLIE | 2007-04-05 | — | — | US | disclosed |
| EP-1624849-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005016237-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | METAP1, METAP2, DNPEP | BRD4 931/4885L3MBTL1 2660/4885METAP2 2/4885 |
| US-20030220371-A1 | Compounds and methods | METAP2, METAP1, DNPEP | BRD4 1152/4885L3MBTL1 2117/4885METAP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.